Assessment of primary malignancy incidence among psoriasis patients on biologic therapy: A retrospective cohort study using the TriNetX Research network

This is supplemental material for the article "Assessment of primary malignancy incidence among psoriasis patients on biologic therapy: A retrospective cohort study using the TriNetX Research network." This study examined whether biologic treatment exposure is an independent risk factor for the subsequent development of primary malignancy in patients with psoriatic diseases. 1) Supplementary Table 1 shows overall characteristics of psoriasis patients with and without biologics therapies, before and after propensity score matching. 2) Supplementary Figure 1 shows flowchart of study population. 3) Supplementary Table 2 shows the incidence of primary malignancy among psoriasis patients treated with biologics compared to those not on biologics at six months, one year, three years, five years, and ten years. 4) Supplementary tables 3-5 show subgroup analyses at six months, one year, three years, five years, and ten years for patients receiving exclusively TNFi, IL-12/23i or IL-23i, and IL-17. 5) Supplementary Table 6 shows the incidence of primary malignancy among patients with psoriatic arthritis at six months, one year, three years, five years, and ten years.